This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth
by Zacks Equity Research
Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.
Company News for Mar 26, 2024
by Zacks Equity Research
Companies in The News:MASI,CLFAMD,UAL
Masimo (MASI) Soars 3.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Add Masimo (MASI) to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
Masimo (MASI) Q4 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Despite strength in the Hearables category, Masimo's (MASI) overall fourth-quarter results reflect soft performances.
Masimo (MASI) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Masimo (MASI) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Masimo (MASI) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 31.58% and 0.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Masimo (MASI) This Year?
by Zacks Equity Research
Here is how Masimo (MASI) and CochLear Ltd. Unsponsored ADR (CHEOY) have performed compared to their sector so far this year.
Masimo (MASI), UCHealth Unite to Improve Care With Telehealth
by Zacks Equity Research
Masimo (MASI) collaborates with UCHealth to boost patient care by combining its latest virtual care technologies with UCHealth's clinical expertise and telehealth innovations.
Earnings Preview: Masimo (MASI) Q4 Earnings Expected to Decline
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Masimo (MASI) to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Masimo's (MASI) MightySat Pulse Oximeter Receives FDA Approval
by Zacks Equity Research
Masimo's (MASI) MightySat Medical Pulse Oximeter receives FDA clearance, which makes it the first FDA-approved pulse oximeter to be available OTC.
GE HealthCare (GEHC) Q4 Earnings Beat, Volume & Price Improve
by Zacks Equity Research
GE HealthCare's (GEHC) fourth-quarter results benefit from continued demand for imaging, patient care and pharmaceutical diagnostic solutions. Sales gain from improved pricing.
If You Invested $1000 in Masimo a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Intuitive Surgical (ISRG) Seeks FDA Nod for Next-Gen da Vinci 5
by Zacks Equity Research
Intuitive Surgical (ISRG) aims to boost its da Vinci portfolio with the addition of its next-generation da Vinci 5 multiport surgical robot.
Intuitive Surgical (ISRG) Q4 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosts procedure sales.
3 Medical Instruments Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
The Zacks Medical - Instruments industry is gaining from the rising demand for digital health offers. However, inflation and staffing shortages continue to disrupt growth. HOLX, MASI and VCYT appear well-poised to brave the challenges.
Can Masimo (MASI) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Masimo (MASI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Masimo (MASI) Just Overtook the 200-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.
Masimo (MASI) Gains on Favorable Ruling in Apple Watch Dispute
by Zacks Equity Research
Masimo (MASI) rides on the continuation of the import ban on certain models of Apple watches using disputed blood oxygen sensors.
Here's How Much a $1000 Investment in Masimo Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics' (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.
What's in Store for Boston Scientific (BSX) in Q4 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.